CRDL Earnings & Financial Statements
Cardiol Therapeutics Inc.
$1.31
-$0.01(-0.76%)
34
Overall
40
Value
40
Tech
23
Quality
Market Cap
$163.36M
Volume
4.58M
52W Range
$0.88 - $2.34
Target Price
$7.99
CRDL earnings and financial statements: Cardiol Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CRDL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | $78.8K |
| Operating income | -$34.32M | -$40.28M | -$29.79M | -$41.34M | -$38.66M |
| EBITDA | -$33.72M | -$40.58M | -$26.45M | -$36.23M | -$38.44M |
| Net income | -$33.82M | -$40.96M | -$26.70M | -$36.45M | -$31.64M |
| EPS (diluted) | $-0.39 | $-0.51 | $-0.44 | $-0.49 | $-0.73 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $23.62M | $31.86M | $36.70M | $62.03M | $87.88M |
| Total liabilities | $5.74M | $7.14M | $8.45M | $9.83M | $11.64M |
| Shareholders’ equity | $17.88M | $24.73M | $28.25M | $52.20M | $76.24M |
| Cash and equivalents | $21.42M | $30.58M | $34.93M | $59.47M | $83.90M |
| Long-term debt | $87.2K | $125.5K | $158.5K | $22.4K | $72.9K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$23.85M | -$25.06M | -$25.18M | -$27.22M | -$23.55M |
| Free cash flow | -$23.88M | -$25.08M | -$25.24M | -$27.30M | -$23.55M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRDL | $1.31 | -0.8% | 4.58M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cardiol Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW